The hr+her2 breast cancer industry trends have seen significant momentum over the past 18 months, driven by innovations and strategic collaborations. Notably, Roche expanded its oncology portfolio through a partnership with Seagen, advancing enfortumab vedotin for HR+/HER2-low subtypes. Meanwhile, Pfizer acquired Seagen in a $43 billion deal, bolstering its pipeline of antibody-drug conjugates (ADCs) targeting HR+/HER2 cancers. Regulatory progress includes the FDA’s 2023 approval of Enhertu (fam-trastuzumab deruxtecan) for HR+/HER2-low patients, reshaping treatment paradigms. Technological advancements, such as AI-driven diagnostic tools for HER2 biomarker detection, have emerged to improve patient stratification. Enterprise trends reflect a shift toward personalized therapies, with companies like Astellas and GSK investing in combination regimens to overcome resistance. Funding has surged, with Mirati Therapeutics securing a $300 million Series C round for its KRAS inhibitors, while Veracyte expanded its liquid biopsy capabilities. These developments underscore a forward-looking industry focused on precision, accessibility, and accelerated drug development.
